Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd in HER2+ Breast Cancer with Brain Metastases
NCT04752059Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Medical University of Vienna. Started Jul 2020; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04752059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752059.